A1 Refereed original research article in a scientific journal

Serum proteomics of mother-infant dyads carrying HLA-conferred type 1 diabetes risk




AuthorsBhosale, Santosh D.; Moulder, Robert; Suomi, Tomi; Ruohtula, Terhi; Honkanen, Jarno; Virtanen, Suvi M.; Ilonen, Jorma; Elo, Laura L.; Knip, Mikael; Lahesmaa, Riitta

PublisherCell Press

Publication year2024

JournaliScience

Journal name in sourceiScience

Article number110048

Volume27

Issue6

ISSN2589-0042

eISSN2589-0042

DOIhttps://doi.org/10.1016/j.isci.2024.110048(external)

Web address https://doi.org/10.1016/j.isci.2024.110048(external)

Self-archived copy’s web addresshttps://research.utu.fi/converis/portal/detail/Publication/404755571(external)


Abstract

In-utero and dietary factors make important contributions towards health and development in early childhood. In this respect, serum proteomics of maturing infants can provide insights into studies of childhood diseases, which together with perinatal proteomes could reveal further biological perspectives. Accordingly, to determine differences between feeding groups and changes in infancy, serum proteomics analyses of mother-infant dyads with HLA-conferred susceptibility to type 1 diabetes (n = 22), weaned to either an extensively hydrolyzed or regular cow’s milk formula, were made. The LC-MS/MS analyses included samples from the beginning of third trimester, the time of delivery, 3 months postpartum, cord blood and samples from the infants at 3, 6, 9 and 12 months. Correlations between ranked protein intensities were detected within the dyads, together with perinatal and age-related changes. Comparison with intestinal permeability data revealed a number of significant correlations, which could merit further consideration in this context.


Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Funding information in the publication
R.L. received funding from the Academy of Finland (grants 292335, 294337, 319280, 31444, 319280, 329277, and 331790), Business Finland and by grants from the JDRF, Sigrid Jusélius Foundation, Jane and Aatos Erkko Foundation, Finnish Diabetes Foundation, and the Finnish Cancer Foundation. L.E. reports grants from the European Research Council ERC (677943), Academy of Finland (296801, 310561, 314443, 329278, 335434, and 335611), and Sigrid Jusélius Foundation during the conduct of the study. R.L. and M.K. were supported by the Academy of Finland, AoF, Centre of Excellence in Molecular Systems Immunology and Physiology Research (2012–2017, grants 250114 and 292482). M.K. also received support from the Sigrid Jusélius Foundation, Helsinki University Hospital Research Funds and the Liv and Hälsa Fund.


Last updated on 2024-05-12 at 12:59